KEGG   PATHWAY: eai05235
Entry
eai05235                    Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Equus asinus (ass)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
eai05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
eai05235

Organism
Equus asinus (ass) [GN:eai]
Gene
106848533  HIF1A; LOW QUALITY PROTEIN: hypoxia-inducible factor 1-alpha [KO:K08268]
106829795  EGF; LOW QUALITY PROTEIN: pro-epidermal growth factor [KO:K04357]
106824133  EGFR; epidermal growth factor receptor isoform X1 [KO:K04361] [EC:2.7.10.1]
106824973  HRAS; GTPase HRas isoform X1 [KO:K02833]
106825548  KRAS; GTPase KRas isoform X2 [KO:K07827]
106829397  GTPase KRas-like [KO:K07827]
106835678  NRAS; GTPase NRas [KO:K07828]
106829345  RAF1; RAF proto-oncogene serine/threonine-protein kinase isoform X1 [KO:K04366] [EC:2.7.11.1]
106830991  LOW QUALITY PROTEIN: RAF proto-oncogene serine/threonine-protein kinase-like [KO:K04366] [EC:2.7.11.1]
106840602  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 isoform X1 [KO:K04368] [EC:2.7.12.2]
106832322  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
106845632  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
106848262  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
106827712  FOS; proto-oncogene c-Fos [KO:K04379]
106833477  JUN; LOW QUALITY PROTEIN: transcription factor AP-1 [KO:K04448]
106848305  EML4; echinoderm microtubule-associated protein-like 4 [KO:K15420]
106837084  ALK; ALK tyrosine kinase receptor isoform X1 [KO:K05119] [EC:2.7.10.1]
106840141  PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X2 [KO:K02649]
106822593  phosphatidylinositol 3-kinase regulatory subunit gamma isoform X1 [KO:K02649]
106824993  PIK3R2; LOW QUALITY PROTEIN: phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
106838100  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922] [EC:2.7.1.153]
106829313  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
106836695  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
106845897  PTEN; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN isoform X1 [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
106835457  AKT3; RAC-gamma serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
106839597  AKT1; RAC-alpha serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
106843289  AKT2; RAC-beta serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
106836676  MTOR; serine/threonine-protein kinase mTOR isoform X3 [KO:K07203] [EC:2.7.11.1]
106833496  RPS6KB2; ribosomal protein S6 kinase beta-2 [KO:K04688] [EC:2.7.11.1]
106841135  RPS6KB1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
106846705  CHUK; inhibitor of nuclear factor kappa-B kinase subunit alpha isoform X1 [KO:K04467] [EC:2.7.11.10]
106828957  IKBKB; inhibitor of nuclear factor kappa-B kinase subunit beta isoform X1 [KO:K07209] [EC:2.7.11.10]
106828814  IKBKG; NF-kappa-B essential modulator isoform X1 [KO:K07210]
106838803  NFKBIA; NF-kappa-B inhibitor alpha [KO:K04734]
106836078  NFKBIB; NF-kappa-B inhibitor beta [KO:K02581]
106828700  NFKBIE; NF-kappa-B inhibitor epsilon [KO:K05872]
106825951  NFKB1; nuclear factor NF-kappa-B p105 subunit isoform X1 [KO:K02580]
106833569  RELA; transcription factor p65 isoform X1 [KO:K04735]
106843591  IFNG; interferon gamma [KO:K04687]
106837196  IFNGR1; interferon gamma receptor 1 [KO:K05132]
106832838  IFNGR2; interferon gamma receptor 2 [KO:K05133]
106838751  JAK1; tyrosine-protein kinase JAK1 isoform X1 [KO:K11217] [EC:2.7.10.2]
106843620  JAK2; tyrosine-protein kinase JAK2 isoform X1 [KO:K04447] [EC:2.7.10.2]
106828796  STAT1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220]
106826327  STAT3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692]
106821799  TLR2; toll-like receptor 2 [KO:K10159]
106824214  TLR4; toll-like receptor 4 isoform X1 [KO:K10160]
106821763  TLR9; toll-like receptor 9 [KO:K10161]
106834020  toll/interleukin-1 receptor domain-containing adapter protein isoform X2 [KO:K05403]
106825588  toll/interleukin-1 receptor domain-containing adapter protein-like [KO:K05403]
106834265  MYD88; myeloid differentiation primary response protein MyD88 isoform X1 [KO:K04729]
106837480  TRAF6; TNF receptor-associated factor 6 [KO:K03175] [EC:2.3.2.27]
106834926  NFATC1; nuclear factor of activated T-cells, cytoplasmic 1 isoform X1 [KO:K04446]
106825560  NFATC2; nuclear factor of activated T-cells, cytoplasmic 2 isoform X1 [KO:K17332]
106822461  NFATC3; LOW QUALITY PROTEIN: nuclear factor of activated T-cells, cytoplasmic 3 [KO:K17333]
106832333  TICAM1; LOW QUALITY PROTEIN: TIR domain-containing adapter molecule 1 [KO:K05842]
106831473  LOW QUALITY PROTEIN: TIR domain-containing adapter molecule 2 [KO:K05409]
106843625  CD274; programmed cell death 1 ligand 1 [KO:K06745]
106844916  PDCD1; programmed cell death protein 1 isoform X1 [KO:K06744]
106847314  PTPN6; tyrosine-protein phosphatase non-receptor type 6 isoform X1 [KO:K05697] [EC:3.1.3.48]
106845198  tyrosine-protein phosphatase non-receptor type 11-like isoform X1 [KO:K07293] [EC:3.1.3.48]
106842252  PTPN11; tyrosine-protein phosphatase non-receptor type 11 isoform X1 [KO:K07293] [EC:3.1.3.48]
106827194  BATF3; basic leucine zipper transcriptional factor ATF-like 3 [KO:K09034]
106833606  BATF2; basic leucine zipper transcriptional factor ATF-like 2 isoform X1 [KO:K09034]
106827698  BATF; basic leucine zipper transcriptional factor ATF-like [KO:K09034]
106822212  CSNK2A2; casein kinase II subunit alpha' isoform X1 [KO:K03097] [EC:2.7.11.1]
106833699  CSNK2A1; casein kinase II subunit alpha [KO:K03097] [EC:2.7.11.1]
106825044  CSNK2B; casein kinase II subunit beta isoform X1 [KO:K03115]
106847327  CD4; T-cell surface glycoprotein CD4 isoform X2 [KO:K06454]
106829050  LCK; tyrosine-protein kinase Lck isoform X1 [KO:K05856] [EC:2.7.10.2]
106840276  CD3E; T-cell surface glycoprotein CD3 epsilon chain isoform X1 [KO:K06451]
106840278  CD3G; T-cell surface glycoprotein CD3 gamma chain [KO:K06452]
106842561  uncharacterized protein LOC106842561 [KO:K10785]
106833872  uncharacterized protein LOC106833872 [KO:K10785]
106841549  CD247; T-cell surface glycoprotein CD3 zeta chain isoform X1 [KO:K06453]
106840277  CD3D; T-cell surface glycoprotein CD3 delta chain [KO:K06450]
106842544  tyrosine-protein kinase ZAP-70 isoform X1 [KO:K07360] [EC:2.7.10.2]
106835525  MAP3K3; mitogen-activated protein kinase kinase kinase 3 isoform X1 [KO:K04421] [EC:2.7.11.25]
106825518  MAP2K3; dual specificity mitogen-activated protein kinase kinase 3 [KO:K04432] [EC:2.7.12.2]
106830236  MAP2K6; dual specificity mitogen-activated protein kinase kinase 6 isoform X2 [KO:K04433] [EC:2.7.12.2]
106824547  MAPK14; mitogen-activated protein kinase 14 isoform X1 [KO:K04441] [EC:2.7.11.24]
106824582  MAPK13; mitogen-activated protein kinase 13 isoform X1 [KO:K04441] [EC:2.7.11.24]
106846005  MAPK12; mitogen-activated protein kinase 12 isoform X1 [KO:K04441] [EC:2.7.11.24]
106846006  MAPK11; mitogen-activated protein kinase 11 isoform X1 [KO:K04441] [EC:2.7.11.24]
106829097  LAT; linker for activation of T-cells family member 1 isoform X1 [KO:K07362]
106834358  PLCG1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 isoform X1 [KO:K01116] [EC:3.1.4.11]
106847712  PPP3CC; serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform isoform X4 [KO:K04348] [EC:3.1.3.16]
106834431  PPP3CA; LOW QUALITY PROTEIN: serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform [KO:K04348] [EC:3.1.3.16]
106842388  PPP3CB; serine/threonine-protein phosphatase 2B catalytic subunit beta isoform isoform X3 [KO:K04348] [EC:3.1.3.16]
106828340  PPP3R1; calcineurin subunit B type 1 isoform X1 [KO:K06268]
106831788  PPP3R2; calcineurin subunit B type 2 [KO:K06268]
106835159  RASGRP1; RAS guanyl-releasing protein 1 isoform X1 [KO:K04350]
106828142  CD28; T-cell-specific surface glycoprotein CD28 isoform X1 [KO:K06470]
106831239  PRKCQ; protein kinase C theta type isoform X1 [KO:K18052] [EC:2.7.11.13]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
eai04010  MAPK signaling pathway
eai04020  Calcium signaling pathway
eai04066  HIF-1 signaling pathway
eai04151  PI3K-Akt signaling pathway
eai04514  Cell adhesion molecules
eai04620  Toll-like receptor signaling pathway
eai04660  T cell receptor signaling pathway
KO pathway
ko05235   
LinkDB

DBGET integrated database retrieval system